Stock listing
ADMA Stock Price, News, Filings & Events — Adma Biologics Inc
Selected listing: ADMA · BOATS · USD · US
This page tracks Adma Biologics Inc's ADMA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ADMA:BOATS. ADMA:BOATS is the stock-level entry point for investors researching Adma Biologics Inc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Adma Biologics Inc, trading under the ticker ADMA, is a public company based in America with a market capitalization of approximately $1.92 billion. The company focuses on developing and manufacturing specialty biologics for the treatment of infectious diseases. Adma Biologics aims to address unmet medical needs through its innovative products and therapies.
- Ticker
- ADMA:BOATS
- Asset type
- Stock
- Market cap
- $2.09B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Adma Biologics Inc ADMA:BOATS stock context
This page tracks Adma Biologics Inc's ADMA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ADMA:BOATS. ADMA:BOATS is the stock-level entry point for investors researching Adma Biologics Inc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Adma Biologics Inc, trading under the ticker ADMA, is a public company based in America with a market capitalization of approximately $1.92 billion. The company focuses on developing and manufacturing specialty biologics for the treatment of infectious diseases. Adma Biologics aims to address unmet medical needs through its innovative products and therapies.
Latest news from Adma Biologics Inc
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & F...
August 7, 2026
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
July 29, 2026
ADMA BIOLOGICS, INC. Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary ...
June 29, 2026
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age ...
May 4, 2026
Adma Biologics Inc earnings calls
ADMA Biologics Inc (ADMA) Q2 2026 Earnings Call
August 5, 2026 · Replay with transcript and chapters
ADMA Biologics Inc (ADMA) Q1 2026 Earnings Call
May 6, 2026 · Replay with transcript and chapters
ADMA Biologics Inc (ADMA) Q4 2025 Earnings Call
February 25, 2026 · Replay with transcript and chapters
ADMA Biologics Inc (ADMA) Q3 2025 Earnings Call
November 5, 2025 · Replay with transcript and chapters
ADMA Biologics Inc (ADMA) Q2 2025 Earnings Call
August 6, 2025 · Replay with transcript and chapters
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call
May 7, 2025 · Replay with transcript and chapters
Research Adma Biologics Inc
Adma Biologics Inc investor report
Review AI stock analysis and investor report context for ADMA:BOATS.
Adma Biologics Inc company profile
View the public company page for Adma Biologics Inc on 6ix.
Adma Biologics Inc news
Read company news and market updates connected to Adma Biologics Inc.
Adma Biologics Inc investor events
Find investor webinars, events, and replay context for Adma Biologics Inc.